AstraZeneca (NASDAQ:AZN – Get Free Report) was upgraded by equities research analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a report issued on Wednesday, FinViz reports.
Several other analysts have also weighed in on AZN. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. TD Cowen increased their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $89.75.
Check Out Our Latest Stock Report on AZN
AstraZeneca Stock Down 7.2 %
Institutional Trading of AstraZeneca
Several hedge funds have recently modified their holdings of AZN. McClarren Financial Advisors Inc. boosted its holdings in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares during the last quarter. GHP Investment Advisors Inc. acquired a new position in AstraZeneca during the 2nd quarter valued at about $26,000. Capital Performance Advisors LLP bought a new position in shares of AstraZeneca in the 3rd quarter valued at about $28,000. Pathway Financial Advisers LLC acquired a new stake in shares of AstraZeneca during the 1st quarter worth approximately $29,000. Finally, RFP Financial Group LLC grew its position in shares of AstraZeneca by 56.3% during the 1st quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock worth $33,000 after buying an additional 178 shares during the period. 20.35% of the stock is owned by institutional investors.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
- Five stocks we like better than AstraZeneca
- Why Invest in 5G? How to Invest in 5G Stocks
- Analysts Signal Big Upside: Top 3 Stocks to Watch Right Now
- Pros And Cons Of Monthly Dividend Stocks
- Bears Misjudged These 3 ETFs: Where Investors Can Find Upside
- Comparing and Trading High PE Ratio Stocks
- Is NVIDIA-Backed SoundHound AI a Buy Ahead of Nov. 12 Earnings?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.